OZEM: Active Management Crucial in the Weight Loss Drug Landscape

The GLP-1 and weight loss drug landscape is teeming with innovation as companies test drugs with different agonists, methods of administration, and frequency of consumption. 

Since inception, the Roundhill GLP-1 & Weight Loss ETF (OZEM) has outperformed its direct peers. As an actively managed ETF, OZEM seeks to provide global exposure to weight loss stocks tackling obesity and supporting weight loss through ground-breaking drug development and innovation. Through October 31, Scholar Rock Holding (SRRK), Chugai Pharmaceuticals (4519 JP), and Eli Lilly (LLY) are the top three positive contributors to OZEM’s total return since inception.

OZEM = Roundhill GLP-1 & Weight Loss ETF 

HRTS = Tema GLP-1, Obesity & Cardiometabolic ETF 

THNR = Amplify Weight Loss Drug & Treatment ETF

The performance data quoted represents past performance and is no guarantee of future results. Investment return and principal value of an investment will fluctuate so that an investor's shares, when redeemed, may be worth more or less than their original cost. Current performance may be lower or higher than the performance data quoted. For the most recent month-end performance, please call 646-661-5441 or visit the Fund’s website at https://www.roundhillinvestments.com/etf/ozem/.

ETF Discussion

Past performance does not guarantee future results. Short term performance, in particular, is not a good indication of the fund’s future performance, and an investment should not be made solely on returns. The standardized performance of each ticker is shown below.

Liquidity: Because these Funds are ETFs, only a limited number of institutional investors (known as “Authorized Participants”) are authorized to purchase and redeem shares directly from the Fund. In addition, there may be a limited number of market makers and/or liquidity providers in the marketplace. To the extent either of the following events occur, shares of the Fund may trade at a material discount to their net asset value (“NAV”) per share and possibly face delisting: (i) Authorized Participants exit the business or otherwise become unable to process creation and/or redemption orders and no other Authorized Participants step forward to perform these services, or (ii) market makers and/or liquidity providers exit the business or significantly reduce their business activities and no other entities step forward to perform their functions.

Guarantees or Insurance: An investment in the Fund is not insured or guaranteed by the Federal Deposit Insurance Corporation or any other government agency.

The ETFs shown are not meant to be a representative sample of all weight loss ETFs. All funds shown are managed differently and do not react the same to economic or market events. The investment objectives, strategies, policies or restrictions of other funds may differ, and more information can be found in their respective prospectuses. Therefore, we generally do not believe it is possible to make direct fund comparisons in an effort to highlight the benefits of a fund versus another.

Roundhill GLP-1 & Weight Loss ETF (OZEM):

Investment Objective: The Fund seeks to provide capital appreciation. The Fund is an actively managed exchange-traded fund (“ETF”) that pursues its investment objective by seeking to provide exposure to companies involved in the development of pharmaceutical drugs and/or supplements that can be utilized to help individuals lose weight, maintain an ideal weight, and/or maintain body composition during weight loss (“GLP-1 & Weight Loss Drugs”).

Expense Ratio: 0.59%

Tema GLP-1, Obesity & Cardiometabolic ETF (HRTS):

Investment Objective: Tema GLP-1, Obesity & Cardiometabolic ETF (the “Fund”) seeks to provide long-term growth of capital. Under normal circumstances, the Tema GLP-1, Obesity & Cardiometabolic ETF (formerly called Tema Obesity & Cardiometabolic ETF) seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in publicly listed companies that derive at least 50% of revenues from products or services related to GLP-1 and the treatment of cardiovascular diseases and/or metabolic diseases, as defined by the Centers for Diseases Control and Preventions (“CDC”).

Expense Ratio: 0.75%

Amplify Weight Loss Drug & Treatment ETF (THNR):

Investment Objective: The Amplify Weight Loss Drug & Treatment ETF seeks investment results that generally correspond to the performance (before fees and expenses) of the VettaFi Weight Loss Drug & Treatment Index.

Expense Ratio: 0.59%

Performance for periods greater than one year shown annualized. The performance data quoted represents past performance and is no guarantee of future results. Investment return and principal value of an investment will fluctuate so that an investor's shares, when redeemed, may be worth more or less than their original cost. Current performance may be lower or higher than the performance data quoted. For the most recent month-end performance, please call 646-661-5441 or visit the Fund’s website at https://www.roundhillinvestments.com/etf/ozem/.